Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-10-12
1995-10-31
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514331, 546192, 546229, 546230, 546237, 546238, 546240, A61K 31445, C07D21118
Patent
active
054629470
ABSTRACT:
A compound of Formula I ##STR1## or a pharmaceutically acceptable salt thereof wherein n is 1 or 2; R.sup.1 and R.sup.2 are independently H (provided only one is H at the same time), --OH, CN, CH.sub.2 CN, 2-- or 4--CF.sub.3, CH.sub.2 CF.sub.3, CH.sub.2 CHF.sub.2, CH.dbd.CF.sub.2, (CH.sub.2).sub.2 CF.sub.3, ethenyl, 2-propenyl, OSO.sub.2 CH.sub.3, OSO.sub.2 CF.sub.3, SSO.sub.2 CF.sub.3, COR, COOR, CON(R).sub.2, SO.sub.x CH.sub.3 (where, x is 0-2), SO.sub.x CF.sub.3, O(CH.sub.2).sub.x CF.sub.3, SO.sub.2 N(R).sub.2, CH.dbd.NOR, COCOOR, COCOON(R).sub.2, C.sub.1-8 alkyls, C.sub.3-8 cycloalkyls, CH.sub.2 OR, CH.sub.2 (R).sub.2, NRSO.sub.2 CF.sub.3, NO.sub.2, halogen, a phenyl at positions 2, 3 or 4, thienyl, furyl, pyrrole, oxazole, thiazole, N-pyrroline, triazole, tetrazole or pyridine; R.sup.3 is hydrogen, CF.sub.3, CH.sub.2 CF.sub.3, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.4 -C.sub.9 cycloalkyl-methyl, C.sub. 2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, --(CH.sub.2).sub.m --R.sup.5 (where m is 1-8), CH.sub.2 SCH.sub.3 or a C.sub.4 -C.sub.8 alkylene bonded to said nitrogen and one of its adjacent carbon atoms inclusive whereby a heterocyclic structure is formed; R.sup.4 and R are independently selected from hydrogen, CF.sub.3, CH.sub.2 CF.sub.3, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.4 -C.sub.9 cycloalkyl-methyl, C.sub.2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, --(CH.sub.2).sub.m --R.sup.5 where m is 1-8; R.sup.5 is phenyl, phenyl (substituted with a CN, CF.sub.3, CH.sub.2 CF.sub.3, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.4 -C.sub.9 cycloalkyl-methyl, C.sub.2 -C.sub.8 alkenyl, C.sub.2 -C.sub.8 alkynyl), 2-thiophenyl, 3-thiophenyl, --NR.sup.6 CONR.sup.6 R.sup.7, or --CONR.sup.6 R.sup.7 ; R.sup.6 and R.sup.7 are independently hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.4 -C.sub.9 cycloalkylmethyl, C.sub.2 -C.sub.8 alkenyl or C.sub.2 -C.sub.8 alkynyl; and with the proviso that when R.sup.1 is CN, R.sup.2 and R.sup.4 are H, R.sup.3 is n-Pr and n is 1, then such compound is a pure enantiomer, and when R.sup.1 or R.sup.2 is OH, halogen, CONH.sub.2 or alkyl, then R.sup.4 is not hydrogen. The Formula I compounds possess selective pharmacological properties and are useful in treating central nervous system disorders related to dopamine receptor activity including depression symptoms, geriatric disorders in the improvement of mental and motor functions, schizophrenia, narcolepsy, MBD, obesitas, and disturbances of sexual functions and impotence.
REFERENCES:
patent: 4188396 (1980-02-01), Haas et al.
patent: 4259337 (1981-03-01), Nedelec et al.
patent: 4263438 (1981-04-01), Althuis et al.
patent: 5068245 (1991-11-01), Zipplies
patent: 5068246 (1991-11-01), Zipplies
K. Bogeso, et al., "Indolizidine and Quinolizidine Derivatives of the Dopamine Autoreceptor Agonist 3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (3-PPP)", J. Med. Chem., 30, pp. 142-150 (1987).
H. Wikstrom, et al., "Resolved 3-(3-Hydroxyphenyl)-N-n-Propylpiperidine and Its Analogues: Central Dopamine Receptor Activity", J. Med. Chem., 27, pp. 1030-1036 (1984).
G. Bianchi, et al., "Farmacologia della 3-fenilazetidina e di alcuni suoi derivati", IL Farmaco, Ed. Sci., vol. 21, No. 2, pp. 131-154 (1966).
H. Wikstrom, et al., "N-Sustituted 1,2,3,4,4a,5,6,10b-Octahydrobenzo[f]quinolines and 3-Phenylpiperidines: Effects on Central Dopamine and o Receptors", J. Med. Chem., 30, pp. 2169-2174 (1987).
Haas, et al., Heterocyctes, Chem. Abst. 46433s, vol. 93 (1980).
D. Clark, et al., "Review Article: Dopamine-Receptor Agonists: Mechanisms Underlying Autoreceptor Selectivity", J. Neural Transmission, 62, pp. 1-52 (1985).
D. Clark, et al., "Review Article: Dopamine-Receptor Agonists: Mechamisms Underlying Autoreceptor Selectivity", J. Neural Transmission, 62, pp. 171-207 (1985).
U. Hacksell, et al., "3-Phenylpiperidines. Central Dopamine-Autoreceptor Stimulating Activity", J. Med. Chem., 24, pp. 1475-1482 (1981).
Andersson Bengt R.
Boije Anna M. P.
Carlsson Per A. E.
Hansson Lars O.
Sonesson Clas A.
Chang Ceila
Corneglio Donald L.
The Upjohn Company
LandOfFree
Centrally acting substituted phenylazacycloalkanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Centrally acting substituted phenylazacycloalkanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Centrally acting substituted phenylazacycloalkanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1772572